healio.com
Healio spoke with Hossein Borghaei, DO, MS, about results from the SAPPHIRE trial presented at this year’s ESMO Congress.“Unfortunately, we realized that for our patients who are being treated upfront with a combination of chemotherapy and immunotherapy, at the time of disease progression, their options are rather limited,” Borghaei, chief of thoracic medical oncology, professor
about 1 year ago